BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amtagvi (lifileucel) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amtagvi (lifileucel)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05607095-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Amtagvi (lifileucel): Phase 1 readout est. (NCT05607095)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1\, Melanoma.\nStudy: A Study of L
 N-144 or LN-145 in People With Advanced Uveal Melanoma\, Undifferentiated 
 Pleomorphic Sarcoma\, Dedifferentiated Liposarcoma\, or Angiosarcoma\nEsti
 mated primary completion: 1 May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05607095
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05640193-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Amtagvi (lifileucel): Phase 1 readout est. (NCT05640193)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1\, Melanoma.\nStudy: A Study of L
 N-144 in People With Metastatic Melanoma to the Brain\nEstimated primary c
 ompletion: November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lifileucel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05640193
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288203-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT07288203)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2\, Melanoma.\nStudy: A Study of L
 ifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07288203
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727904-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Amtagvi (lifileucel): Phase 3 readout est. (NCT05727904)
DESCRIPTION:Amtagvi (lifileucel)\, phase 3\, Melanoma.\nStudy: Study to Inv
 estigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab
  Alone in Participants With Untreated Advanced Melanoma.\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/lifileucel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05727904
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06481592-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT06481592)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2.\nStudy: A Study of Lifileucel (
 Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer
 .\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06481592
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700121-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Amtagvi (lifileucel): Phase 1 readout est. (NCT07700121)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1\, Melanoma.\nStudy: PICSTAT Pilo
 t Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma\nE
 stimated primary completion: 1 October 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07700121
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940739-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Amtagvi (lifileucel): Phase 1/2 readout est. (NCT06940739)
DESCRIPTION:Amtagvi (lifileucel)\, phase 1/2\, Melanoma.\nStudy: A Study to
  Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced M
 elanoma Who Will Receive Lifileucel\nEstimated primary completion: June 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lifileucel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06940739
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741877-10883@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20330901
DTEND;VALUE=DATE:20330902
SUMMARY:Amtagvi (lifileucel): Phase 2 readout est. (NCT07741877)
DESCRIPTION:Amtagvi (lifileucel)\, phase 2.\nStudy: A Study of Lifileucel (
 Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcom
 a\nEstimated primary completion: 1 September 2033. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lifileucel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07741877
URL:https://assetmemo.bio/drug/lifileucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
